S. Claiborne Johnston
S. Claiborne Johnston, M.D., Ph.D., has served as the inaugural Dean of the Dell Medical School at the University of Texas, Austin since March 2014. In this position, he plans to build a world-class academic medical center focused on providing new models of education and healthcare delivery. He is also Professor of Neurology, specializing in stroke care and research. Clay arrived in Austin from the University of California, San Francisco, where he directed the Clinical and Translational Science Institute, overseeing the planning, development, and implementation of a $112-million, five-year, National Institutes of Health (NIH) grant award, the second largest among the 60-member national CTSA consortium. Working with a team of 300+ faculty and staff serving all four schools at UCSF, Clay positioned the Institute as a catalyst in efforts to accelerate research to improve health on campus and throughout the University of California system. He founded the Center for Healthcare Value at UCSF in order to engage faculty and trainees in lowering the costs of healthcare while improving quality. He was also instrumental in cultivating and securing partnerships with leading biotech companies, foundations, and private funders. In his role as Associate Vice Chancellor of Research, Clay was integrally involved in efforts to realize the University's vision of being the world's preeminent health sciences innovator. After receiving his undergraduate education at Amherst College, he completed medical school at Harvard University. He later received a PhD in epidemiology from the University of California, Berkeley, and was a resident in Neurology at UCSF, where he later trained in Vascular Neurology. During his 20 years at UCSF, he rose the academic ranks to Professor of Neurology and Epidemiology, and directed the Stroke Service. Clay has authored more than 300 publications in scientific journals and has won several national awards for his research and teaching. In particular, he has published extensively in the prevention and treatment of stroke and transient ischemic attack. He is perhaps best known for his studies describing the short-term risk of stroke in patients with transient ischemic attack and identifying patients at greatest risk, and also for his work related to measuring the impact of research. He has led several large cohort studies of cerebrovascular disease and three international multicenter randomized trials, two of which are ongoing.